SOMA FDA MedWatch Direct Reports Summary
These tables and charts are created from 297 voluntary U.S. reports for SOMA (CARISOPRODOL) reported by individuals to the FDA via the MedWatch Reporting System from 2004 through April 28, 2026.
For a summary of adverse events including mandatory reports submitted by pharmaceutical companies (all countries and all reporter types) to the FAERS database, View FDA FAERS SOMA Report.
Top Adverse Effects Associated with SOMA (from U.S. FDA Medwatch Reports)
Side Effect # of FDA Reports 1 HEADACHE 30 2 PAIN 24 3 INSOMNIA 21 4 NAUSEA 20 5 PRODUCT SUBSTITUTION ISSUE 20 6 ANXIETY 19 7 DRUG INEFFECTIVE 18 8 BACK PAIN 17 9 LACK OF STRENGTH AND ENERGY (ASTHENIA) 16 10 DIZZINESS 16 11 VOMITING 16 12 MUSCLE SPASMS 15 13 JOINT PAIN 14 14 DIARRHEA 14 15 ABDOMINAL PAIN UPPER 13 16 SHORTNESS OF BREATH 13 17 FATIGUE 12 18 DEPRESSION 11 19 EXCESS SWEATING 11 20 ITCHING 11 21 RASH 11 22 DEATH 10 23 FALL 10 24 PRODUCT QUALITY ISSUE 10 25 DROWSINESS 10
SOMA Total Medwatch Safety Reports by Patient Sex
| Male | Female | Unknown | Total |
|---|---|---|---|
| 85 | 206 | 6 | 297 |
| Medwatch Reporter Type | Count |
| Consumer | 116 |
| Physician | 11 |
| Pharmacist | 42 |
| Other Health Professional | 46 |
| Top Indications | |
Type of Outcome Reported
Serious: 223
Not Serious: 74
Note: A serious outcome means the adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition.
Suspected Role
Primary Suspect: 297
Concomitant Drugs: 282
Note: A single MedWatch report can list more than one drug. This summary includes SOMA identified as the suspect drug or as a concomitantly taken drug.
FDA Safety-Related Labeling Changes
SOMA (CARISOPRODOL) Rx Drug:
FDA Safety-related Labeling Changes
HUMATROPE (SOMATROPIN RECOMBINANT) Rx Drug:
FDA Safety-related Labeling Changes
In pediatric patients, Slipped capital femoral epiphysis may lead to osteonecrosis.
SAIZEN (SOMATROPIN RECOMBINANT) Rx Drug:
FDA Safety-related Labeling Changes
ZOMACTON (SOMATROPIN RECOMBINANT) Discontinued Drug:
FDA Safety-related Labeling Changes
NUTROPIN (SOMATROPIN RECOMBINANT) Rx Drug:
FDA Safety-related Labeling Changes
In pediatric patients, Slipped capital femoral epiphysis may lead to osteonecrosis.
GENOTROPIN (SOMATROPIN RECOMBINANT) Rx Drug:
FDA Safety-related Labeling Changes
In pediatric patients, Slipped capital femoral epiphysis may lead to osteonecrosis.
NUTROPIN AQ (SOMATROPIN RECOMBINANT) Discontinued Drug:
FDA Safety-related Labeling Changes
In pediatric patients, Slipped capital femoral epiphysis may lead to osteonecrosis.
SEROSTIM (SOMATROPIN RECOMBINANT) Discontinued Drug:
FDA Safety-related Labeling Changes
NORDITROPIN (SOMATROPIN RECOMBINANT) Rx Drug:
FDA Safety-related Labeling Changes
Gynecomastia warning. Do not store NORDITROPIN directly next to the cooling element in the refrigerator. Slipped capital femoral epiphysis reported, pediatric patients.
OMNITROPE (SOMATROPIN RECOMBINANT) Rx Drug:
FDA Safety-related Labeling Changes
In pediatric patients, Slipped capital femoral epiphysis may lead to osteonecrosis.
SOGROYA (SOMAPACITAN-BECO) Biological Drug:
FDA Safety-related Labeling Changes
In pediatric patients, Slipped capital femoral epiphysis may lead to osteonecrosis.
Have experience (good or bad) with SOGROYA? Rate SOGROYA at Ask a Patient.
For serious adverse events, report them to the FDA by contacting the drug manufacturer or report directly through the MedWatch voluntary reporting form.
NOTES
This report, created by AskaPatient.com, is derived from U.S. drug-related adverse event cases that were reported directly to the FDA using the voluntary MedWatch online or paper reporting system. MedWatch is the voluntary FDA system for consumers, physicians, and others to directly report adverse reactions. The Medwatch initiative was launched in 1993 as a voluntary reporting program for consumers, physicians and other healthcare practitioners.
After processing the received forms, the FDA adds the MedWatch reports to the FDA Adverse Events Reporting System(or FAERS database.) Click here for the complete FAERS report summary, which includes mandatory reports submitted by pharmaceutical companies (worldwide) combined with the MedWatch reports. MedWatch Reports only represent about 5% of the FAERS database. For more, read "Does the FDA's Rapidly Growing Database of Adverse Events Improve Drug Safety?"
The data in this report was obtained from Open FDA. Data was last updated to include reports through January 27, 2026. The reactions, side effects, or "adverse events," represent up to the 20 most frequently occuring events in the database for a drug related to the event.
Open FDA states that it only includes the most recent version of a case report. It also adds the disclaimer: "Do not rely on Open FDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated."
FDA uses the "MedDRA" classification system to describe reported adverse
reactions. MedDRA is a standardized medical terminology that facilitates
sharing of regulatory information internationally. In some cases, "patient
friendly" terms for the layman designated by MedDRA have been substituted
for medical jargon. Please
contact us
with questions about this report.